Lenvatinib Mesylate Intermediate CAS 15568-85-1 Mimọ> 97.0% (HPLC) Ile-iṣẹ

Apejuwe kukuru:

5- (Methoxymethylene) -2,2-Dimethyl-1,3-Dioxane-4,6-Dion

CAS: 15568-85-1

Mimọ:> 97.0% (HPLC)

Irisi: Yellow Powder

Agbedemeji ti Lenvatinib Mesylate CAS 857890-39-2

Olubasọrọ: Dokita Alvin Huang

Mobile/Wechat/WhatsApp: +86-15026746401

E-Mail: alvin@ruifuchem.com


Alaye ọja

Jẹmọ Products

ọja Tags

Apejuwe:

Kemikali Properties:

Orukọ Kemikali 5- (Methoxymethylene) -2,2-Dimethyl-1,3-Dioxane-4,6-Dion
Awọn itumọ ọrọ sisọ 5- (Methoxymethylene) Acid Meldrum;Cabozantinib Aimọ 56;Lenvatinib aimọ 79
Nọmba CAS 15568-85-1
NỌMBA CAT RF-PI1967
Iṣura Ipo Ninu Iṣura, Iwọn iṣelọpọ Ti o to Awọn Toonu
Ilana molikula C8H10O5
Òṣuwọn Molikula 186.16
Ojuami Iyo 132.0 ~ 134.0 ℃
iwuwo 1,297 ± 0,06 g / cm3
Brand Ruifu Kemikali

Awọn pato:

Nkan Awọn pato
Ifarahan Iyẹfun Odo
1 H NMR julọ.Oniranran Ni ibamu Pẹlu Be
Mimọ / Analysis Ọna
> 97.0% (HPLC)
Lapapọ Awọn Aimọ <3.00%
Igbeyewo Standard Standard Enterprise
Lilo Agbedemeji ti Lenvatinib Mesylate (CAS: 857890-39-2)

Package & Ibi ipamọ:

Package: Igo, apo bankanje aluminiomu, 25kg / Paali ilu, tabi gẹgẹ bi ibeere alabara

Ipò Ìpamọ́:Fipamọ sinu awọn apoti ti a fi edidi ni itura ati ibi gbigbẹ;Dabobo lati ina ati ọrinrin

Awọn anfani:

1

FAQ:

Ohun elo:

5- (Methoxymethylene) -2,2-Dimethyl-1,3-Dioxane-4,6-Dione (CAS: 15568-85-1) jẹ agbedemeji ti Lenvatinib Mesylate (CAS: 857890-39-2).Lenvatinib jẹ oogun akàn tairodu ti o ni idagbasoke nipasẹ Eisai Corporation of Japan (koodu: E7080), ti o jẹ ti oludena ti oral multi-receptor tyrosine kinase (RTK) ati pe o le ṣe idiwọ iṣẹ ṣiṣe kinase ti ifosiwewe idagbasoke endothelial ti iṣan (VEGF) Awọn olugba VEGFR1 (VEGF) FLT1), VEGFR2 (KDR), ati VEGFR3 (FLT4).Lenvatinib tun le dẹkun ilowosi ti awọn RTK miiran ni angiogenesis pathological, idagbasoke tumo, ati ilọsiwaju akàn ayafi fun awọn iṣẹ cellular deede wọn pẹlu fibroblast growth factor (FGF) awọn olugba FGFR1, 2, 3, ati 4;Olugba ifosiwewe idagbasoke ti platelet (PDGFR [alpha]), KIT, ati RET.[Awọn itọkasi]: Lenvatinib jẹ o dara fun itọju awọn alaisan ti akàn tairodu ti iṣipopada agbegbe tabi iru metastasis, iru ilọsiwaju ati ipanilara iodine-refractory differentiated type.Ni Oṣu Keji ọjọ 13, Ọdun 2015, US FDA fọwọsi oogun anticancer Lenvatinib fun itọju akàn tairodu.Lenvatinib jẹ inhibitor enzymu-pupọ-afojusun, ti o lagbara lati dena VEGFR2 ati VEGFR3 (igbasilẹ ifosiwewe idagbasoke endothelial ti iṣan).Orukọ iṣowo ti Lenvatinib jẹ Lenvima.Ni Oṣu Karun ọjọ 20, Ọdun 2015, Ile-iṣẹ Oogun Yuroopu (EMA) fọwọsi Lenvatinib fun itọju invasive, ilọsiwaju ti agbegbe tabi iyatọ metastatic (papillary, follicular, Iru Hurthle) akàn tairodu (DTC).Ninu idanwo naa, akoko iwalaaye agbedemeji fun awọn alaisan ti DTC ipanilara iodine-refractory ti a tọju pẹlu Lenvatinib jẹ oṣu 18 lakoko ti iye fun awọn alaisan ti o gba placebo jẹ oṣu 3 nikan.

Kọ ifiranṣẹ rẹ nibi ki o si fi si wa